CLSA Premium (HKSE:06877) ROCE % : 2.13% (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is CLSA Premium ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CLSA Premium's annualized ROCE % for the quarter that ended in Jun. 2024 was 2.13%.

CLSA Premium ROCE % Historical Data

The historical data trend for CLSA Premium's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CLSA Premium ROCE % Chart

CLSA Premium Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-21.69

-15.92

-4.26

6.19

-1.18

CLSA Premium Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial															5.01	3.98	8.35	2.13	-4.43

CLSA Premium ROCE % Calculation

CLSA Premium's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	14.575	/	( ( (284.31 - 53.51)	+	(251.775 - 11.91) )	/ 2 )
	=	14.575	/	( (230.8	+	239.865)	/ 2 )
	=	14.575	/	235.3325
	=	6.19 %

CLSA Premium's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	5.162	/	( ( (251.775 - 11.91)	+	(262.097 - 16.491) )	/ 2 )
	=	5.162	/	( ( 239.865	+	245.606 )	/ 2 )
	=	5.162	/	242.7355
	=	2.13 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

CLSA Premium (HKSE:06877) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CLSA Premium ROCE % Related Terms

Thank you for viewing the detailed overview of CLSA Premium's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CLSA Premium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Capital Markets » CLSA Premium Ltd (HKSE:06877) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

88 Queensway, Suite 804, Level 8, One Pacific Place, Hong Kong, HKG

Website

https://www.clsapremium.com

CLSA Premium Ltd operates in the financial services sector. It provides leveraged forex and other trading, cash dealing, sales of healthcare products and other services.. The operating segments of the group are the Margin dealing segment. Unallocated segment, Healthcare products segment, The margin dealing segment is engaged in the provision of leveraged foreign exchange, commodity and index trading services in Australia, Hong Kong and New Zealand. The healthcare products segment engages in the sales of healthcare products. It has a business presence in Hong Kong, Australia, New Zealand and Other countries.

Executives

Beijing Tong Ren Tang (cayman) Limited	2101 Beneficial owner
Top Eminent Invest Co., Ltd.	2201 Interest of corporation controlled by you
Ji Guangfei	2201 Interest of corporation controlled by you
Citic Securities Company Limited	2201 Interest of corporation controlled by you
Calypso International Investment Co., Limited	2101 Beneficial owner
Ci Hang Dong Xi Fang Wen Jiao Jiao Liu Ji Jin Hui You Xian Gong Si	2201 Interest of corporation controlled by you
Hai Hang Su Yun Tou Zi Shang Hai You Xian Gong Si	2201 Interest of corporation controlled by you
Hai Nan Sheng Ci Hang Gong Yi Ji Jin Hui	2201 Interest of corporation controlled by you

CLSA Premium Headlines

No Headlines